Based in Philadelphia, PA, Passage Bio collaborates with the University of Pennsylvania's Gene Therapy Program and Orphan Disease Center to conduct preclinical work and natural history studies, respectively. The company's pipeline includes optimized gene therapies for CNS disorders such as GM1 gangliosidosis, Krabbe disease, and Frontotemporal dementia. Passage Bio's new laboratory in Hopewell, New Jersey, will help the company evolve the standard for biotech innovation and development.